Covid-19 has been the dominant topic in scientific publishing in the biomedical field in the last two years. In the earlier period of the pandemic, studies have explored potential pharmacological treatments based on repurposed drugs. This was followed by large clinical trials, such as the RECOVERY trial, which answered many questions about the efficacy of existing drugs and led to the approval of some of them. More recently, the approval, and the demonstration of the efficacy of vaccines and specific antiviral drugs, have been key to facing the pandemic.
The inflammatory response triggered by a “cytokine storm” is a major mechanism targeted by approved drugs, which include specific anti-inflammatory molecules such as dexamethasone and tocilizumab (anti-IL-6 receptor antibody).
In consideration of the importance of inflammation in Covid-19 pathogenesis, the present Research Topic will focus on studies aimed at characterizing how infection with SARS-Cov2 triggers inflammation and how this contributes to the pathology.
What type of manuscripts will be considered. The Research Topic will focus on inflammation as a disease mechanism. We will consider studies in Covid-19 patients, as well as using in vitro or animal models of SARS-Cov2 infection dealing with the mechanisms triggering inflammation, and its pathogenic, diagnostic, or prognostic role. This may include primary research or review articles.
What type of manuscripts will NOT be considered. Studies on inflammation in non-Covid-19 diseases; studies in the field of pharmacology and therapeutics (e.g., repurposed drugs and natural compounds), which would better fit a pharmacology section/journal.
Covid-19 has been the dominant topic in scientific publishing in the biomedical field in the last two years. In the earlier period of the pandemic, studies have explored potential pharmacological treatments based on repurposed drugs. This was followed by large clinical trials, such as the RECOVERY trial, which answered many questions about the efficacy of existing drugs and led to the approval of some of them. More recently, the approval, and the demonstration of the efficacy of vaccines and specific antiviral drugs, have been key to facing the pandemic.
The inflammatory response triggered by a “cytokine storm” is a major mechanism targeted by approved drugs, which include specific anti-inflammatory molecules such as dexamethasone and tocilizumab (anti-IL-6 receptor antibody).
In consideration of the importance of inflammation in Covid-19 pathogenesis, the present Research Topic will focus on studies aimed at characterizing how infection with SARS-Cov2 triggers inflammation and how this contributes to the pathology.
What type of manuscripts will be considered. The Research Topic will focus on inflammation as a disease mechanism. We will consider studies in Covid-19 patients, as well as using in vitro or animal models of SARS-Cov2 infection dealing with the mechanisms triggering inflammation, and its pathogenic, diagnostic, or prognostic role. This may include primary research or review articles.
What type of manuscripts will NOT be considered. Studies on inflammation in non-Covid-19 diseases; studies in the field of pharmacology and therapeutics (e.g., repurposed drugs and natural compounds), which would better fit a pharmacology section/journal.
